🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07505303
Active, not recruiting Phase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 · tracked via the Priya Life Science USA tracker
Sponsor
Eccogene
Phase
Phase 2
Started
2026-03-23
Last updated
2026-06-25

Condition(s) studied

Adult ObesityWeight Management

Investigational drug(s) / intervention(s)

ECC4703PlaceboSemaglutide

ECC4703: orally QD

Placebo: orally QD

Semaglutide: SC once weekly

Study summary

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Capable of providing written informed consent and complying with all trial procedures. 2. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential). 3. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening. 4. HbA1c ≤6.5%. 5. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula). 6. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9). Exclusion Criteria: 1. History or current diagnosis of type 1 or type 2 diabetes mellitus. 2. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication. 3. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome. 4. Use of GLP-1 agonist treatment within the last 6 months prior to screening. 5. History or current evidence of a pituitary disorder. 6. Have current treatment with or history (within 3 months prior to screening) of treatment with medications that may cause significant weight gain. 7. ALT or AST \>1.5×ULN, or ALP \>1.5×ULN at screening. 8. Documented evidence or clinical signs/symptoms of advanced liver disease including liver cirrhosis, portal hypertension, or hepatic decompensation. 9. History of significant alcohol consumption for \>3 consecutive months within a year prior to screening. 10. Current or past therapy with THR-β agonists (eg, resmetirom). 11. Active untreated hyperthyroidism or hyperthyroidism currently treated with antithyroid medications including methimazole or propylthiouracil. 12. Clinically significant thyroid dysfunction including uncontrolled hypothyroidism or hyperthyroidism. 13. History of bariatric surgery, fitting of a weight loss device, or intestinal bypass surgery within 5 years prior to screening. 14. History of major surgery within 8 weeks prior to screening. 15. Clinically relevant acute or chronic medical condition or unstable disease of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic system.

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
Central Research Associates - Flourish - PPDS Birmingham Alabama
Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS Anaheim California
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS Los Alamitos California
AES - DRS - Optimal Research Florida - Melbourne Melbourne Florida
ForCare Clinical Research - CenExel FCR - PPDS Tampa Florida
Atlanta Center for Medical Research - CenExel ACMR - PPDS Atlanta Georgia
iResearch Atlanta - CenExel - PPDS Decatur Georgia
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis Richfield Minnesota
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS Omaha Nebraska
Velocity Clinical Research - Durham - PPDS Durham North Carolina
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS Cincinnati Ohio
Velocity Clinical Research - Providence - PPDS East Greenwich Rhode Island
Velocity Clinical Research - Dallas - PPDS Dallas Texas
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio San Antonio Texas
Flourish Research - San Antonio - PPDS San Antonio Texas

On this site

📄 Ozempic (semaglutide) drug profile →

More Eccogene trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07505303 on ClinicalTrials.gov ↗ ← All trials in the USA